ACE-031
Also known as: ACVR2B-Fc, Myostatin Inhibitor
A myostatin/activin inhibitor for muscle growth and preservation.
Overview
ACE-031 is a soluble form of activin receptor type IIB (ACVR2B) that acts as a decoy receptor, binding myostatin and related ligands to promote muscle growth.
Mechanism of Action
Binds and neutralizes myostatin, activin A, and GDF-11, negative regulators of muscle mass. Prevents these ligands from signaling through native receptors, disinhibiting muscle growth pathways.
Pharmacokinetics
Long half-life (weeks) due to Fc fusion. Monthly dosing feasible.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research
0.1-0.3 mg/kg
Every 2 weeks
Variable
Clinical trial dosing
Research Areas
Key Research Findings
- 1Increased lean body mass in healthy volunteers
- 2Muscle benefits in Duchenne muscular dystrophy trials
- 3Development paused due to epistaxis and telangiectasia events
Side Effects & Contraindications
Reported Side Effects
- Epistaxis
- Telangiectasia
- Gum bleeding
Contraindications
- Vascular abnormalities
- Bleeding disorders
Safety Considerations
Development halted due to vascular side effects (nosebleeds, telangiectasia). Alternative approaches being developed.
Storage Requirements
Store at 2-8C
Scientific References
- 1